相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hypoxia inducible factor-1-independent pathways in tumor angiogenesis
Yusuke Mizukami et al.
CLINICAL CANCER RESEARCH (2007)
Making a tumour's bed: glioblastoma stem cells and the vascular niche
Richard J. Gilbertson et al.
NATURE REVIEWS CANCER (2007)
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma
Sophie de Boueard et al.
NEURO-ONCOLOGY (2007)
Antiangiogenic strategies on defense: On the possibility of blocking rebounds by the tumor vasculature after chemotheraphy
Yuval Shaked et al.
CANCER RESEARCH (2007)
Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging
Alan Jackson et al.
CLINICAL CANCER RESEARCH (2007)
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
Chris Folkins et al.
CANCER RESEARCH (2007)
Expression of VEGFR3 in glioma endothelium correlates with tumor grade
S. J. Grau et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma
Phyllis R. Wachsberger et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Venous thromboembolism and survival in patients with high-grade glioma
Ralph Simanek et al.
NEURO-ONCOLOGY (2007)
Insulin-like growth factor type I biology and targeting in malignant gliomas
J. Trojan et al.
NEUROSCIENCE (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Effect of bevacizumab on radiation necrosis of the brain
Javier Gonzalez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A perivascular niche for brain tumor stem cells
Christopher Calabrese et al.
CANCER CELL (2007)
A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR
Elizabeth Bullitt et al.
NEUROIMAGE (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma
Thomas J. Semrad et al.
JOURNAL OF NEUROSURGERY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates
Lijo Simpson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice
Christopher G. Willett et al.
SEMINARS IN ONCOLOGY (2006)
Vascular endothelial growth factor signaling pathways: Therapeutic perspective
Marcin Kowanetz et al.
CLINICAL CANCER RESEARCH (2006)
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
Shideng Bao et al.
CANCER RESEARCH (2006)
Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker
Nola Hylton
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma
Christopher E. Pelloski et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of angiogenesis in gliomas
O. Kargiotis et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
LX Sun et al.
CANCER CELL (2006)
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2006)
Differential CD 146 expression on circulating versus tissue endothelial cells in rectal cancer patients: Implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy
DG Duda et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Integrins and angiogenesis: A sticky business
G Serini et al.
EXPERIMENTAL CELL RESEARCH (2006)
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
SB Wedam et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer
AM Jubb et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
RK Jain et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis
Yuan Rong et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
JN Rich et al.
CLINICAL CANCER RESEARCH (2005)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
HL Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The role of pericytes in blood-vessel formation and maintenance
G Bergers et al.
NEURO-ONCOLOGY (2005)
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
R Abounader et al.
NEURO-ONCOLOGY (2005)
Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice
LM Brubaker et al.
CANCER RESEARCH (2005)
Inhibition of αvβ3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy
A Abdollahi et al.
CLINICAL CANCER RESEARCH (2005)
Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors
DQ Ma et al.
CANCER RESEARCH (2005)
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
AL Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
B Kaur et al.
NEURO-ONCOLOGY (2005)
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
J Drevs et al.
ANNALS OF ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas
MR Farhadi et al.
JOURNAL OF NEUROSURGERY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Integrin signalling during tumour progression
WJ Guo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
A Östman
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
TT Batchelor et al.
NEURO-ONCOLOGY (2004)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
Genetic and hypoxic regulation of angiogenesis in gliomas
B Kaur et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells
I Rajantie et al.
BLOOD (2004)
Quantification of blood flow in brain tumors:: Comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging
C Warmuth et al.
RADIOLOGY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-α, angiostatin, or endostatin
S De Boüard et al.
HUMAN GENE THERAPY (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
TF Cloughesy et al.
CANCER (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Dynamic susceptibility contrast-enhanced echo-planar imaging of cerebral gliomas -: Effect of contrast medium extravasation
M Essig et al.
ACTA RADIOLOGICA (2002)
Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch
D Lando et al.
SCIENCE (2002)
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme
MC Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2002)
Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging
JM Provenzale et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2002)
Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy
M Fuss et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway
K Clarke et al.
BRITISH JOURNAL OF CANCER (2001)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G Bergers et al.
NATURE CELL BIOLOGY (2000)
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
JL Rubenstein et al.
NEOPLASIA (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
